Want to see CGON full AI Analyst Report?
CGON Stock Chart & Stats
$69.32
$2.37(3.42%)
At close: 4:00 PM EDT
$69.32
$2.37(3.42%)
Day’s Range― - ―
52-Week Range$23.65 - $77.00
Previous Close$30.46
Volume104.85K
Average Volume (3M)1.14M
Market Cap
$6.28B
Enterprise Value$4.65K
Total Cash (Recent Filing)$1.03B
Total Debt (Recent Filing)$8.82M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Nov 12, 2026EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.70
Shares Outstanding88,202,480
10 Day Avg. Volume953,036
30 Day Avg. Volume1,136,525
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)4.26
Price to Sales (P/S)794.47
P/FCF Ratio-24.23
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$91.17Price Target Upside31.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-3.2
Revenue Forecast (FY)$11.05M
Bulls Say, Bears Say
Bulls Say
Cash RunwayA billion-dollar liquidity cushion provides durable financial flexibility to fund pivotal trials, regulatory submissions, manufacturing scale-up and commercial-readiness without immediate reliance on dilutive financing. This supports execution through key clinical readouts and near-term commercialization activities.
Late‑stage Clinical ProgressAdvancement to late-stage readouts plus peer-reviewed publication materially raises the probability of regulatory review and clinician acceptance. Durable clinical validation strengthens the approval pathway and future commercial adoption, reducing binary development risk compared with earlier-stage programs.
Very Low LeverageMinimal debt levels lower financial distress risk and preserve strategic optionality. This balance-sheet strength allows CG Oncology to invest in R&D, manufacturing and commercialization or pursue partnerships/M&A without large fixed financing costs that could constrain long-term program execution.
Bears Say
High Cash BurnSustained negative operating and free cash flow at this magnitude will materially erode liquidity over time if not reduced or offset by approvals, partnerships or new financing. High burn increases probability of dilution or program cutbacks and puts pressure on capital allocation decisions.
Very Large Operating LossesDeep and persistent operating losses indicate the business is not generating scalable margins today. Negative gross profit suggests costs currently exceed revenues, limiting the firm’s ability to self-fund growth and raising the need for external capital until profitable commercialization is achieved.
Limited Revenue BaseRevenue remains immaterial compared with R&D and SG&A spend, so operational sustainability depends on future approvals or external funding. Small base revenues mean even healthy growth rates will take time to offset cash burn, keeping financing risk elevated over the medium term.
CG Oncology, Inc. News
CGON FAQ
What was CG Oncology, Inc.’s price range in the past 12 months?
CG Oncology, Inc. lowest stock price was $23.65 and its highest was $77.00 in the past 12 months.
What is CG Oncology, Inc.’s market cap?
CG Oncology, Inc.’s market cap is $6.28B.
When is CG Oncology, Inc.’s upcoming earnings report date?
CG Oncology, Inc.’s upcoming earnings report date is Nov 12, 2026 which is in 96 days.
How were CG Oncology, Inc.’s earnings last quarter?
CG Oncology, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.9 earnings per share for the quarter, missing the consensus estimate of -$0.664 by -$0.236.
Is CG Oncology, Inc. overvalued?
According to Wall Street analysts CG Oncology, Inc.’s price is currently Undervalued.
Does CG Oncology, Inc. pay dividends?
CG Oncology, Inc. does not currently pay dividends.
What is CG Oncology, Inc.’s EPS estimate?
CG Oncology, Inc.’s EPS estimate is -0.81.
How many shares outstanding does CG Oncology, Inc. have?
CG Oncology, Inc. has 88,202,480 shares outstanding.
What happened to CG Oncology, Inc.’s price movement after its last earnings report?
CG Oncology, Inc. reported an EPS of -$0.9 in its last earnings report, missing expectations of -$0.664. Following the earnings report the stock price went up 3.355%.
Which hedge fund is a major shareholder of CG Oncology, Inc.?
Currently, no hedge funds are holding shares in CGON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CG Oncology, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$91.17 (31.52% Upside)
$91.17 (31.52% Upside)
Blogger Sentiment
Bullish
CGON Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $24.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
165.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
55.90%
Trailing 12-Months
Company Description
CG Oncology, Inc.
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
CGON Stock 12 Month Forecast
Average Price Target
$91.17
▲(31.52% Upside)
Technical Analysis
Cogent Biosciences
―
Oric Pharmaceuticals
―
Relay Therapeutics
―
Tango Therapeutics
―
Erasca
―
Ownership Overview
10.35% Insiders
28.66% Mutual Funds
1.43% Other Institutional Investors
43.42% Public Companies and
Individual Investors